GlaxoSmithKline Consumer Healthcare Ltd. said its normalized net income for the fiscal first quarter ended June 30 amounted to 29.47 Indian rupees per share, compared with the S&P Capital IQ consensus estimate of 32.38 rupees per share.
EPS increased 8.8% year over year from 27.07 rupees.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 1.24 billion rupees, a gain of 8.8% from 1.14 billion rupees in the prior-year period.
The normalized profit margin rose to 13.4% from 13.4% in the year-earlier period.
Total revenue grew 8.0% year over year to 9.22 billion rupees from 8.53 billion rupees, and total operating expenses increased 8.4% on an annual basis to 7.69 billion rupees from 7.09 billion rupees.
Reported net income increased 8.5% from the prior-year period to 1.30 billion rupees, or 30.94 rupees per share, from 1.20 billion rupees, or 28.52 rupees per share.
As of Aug. 6, US$1 was equivalent to 61.34 Indian rupees.
